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Compounding  
for analgesia
By Dr Alison Haywood and Professor Beverley Glass
solutions through compounding
Rationale for 
compounding in analgesia
Pain, a unique symptom that may 
vary from patient to patient, can be 
divided into two categories: acute and 
chronic pain. Today, many healthcare 
practitioners realise that chronic 
pain is a very complex problem, and 
adequate treatment takes effort, 
thought, and in-depth problem solving 
skills, particularly in areas such as 
palliative care. 
When considering dosage forms 
available for pain management 
(Figure 1), oral solid dosage forms 
are often the first choice, due 
to ease of administration. If a 
patient is unable to swallow oral 
solids, a commercially available 
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Learning objectives 
After reading this article you should 
be able to:
Describe when compounding of •	
medicines for analgesia might be 
necessary
Describe suppositories as a •	
compounded dosage form for 
meeting specific patient needs in 
analgesia
Counsel patients on the •	
appropriate use of compounded 
suppositories.
Competencies addressed: 
4.2.2, 5.1.2, 5.1.4, 5.1.5, 5.2.7
oral liquid (e.g. hydromorphone, 
morphine, methadone, oxycodone, 
tramadol, naproxen, diclofenac, 
ibuprofen)1 or alternative oral dosage 
form that does not need to be 
swallowed (e.g. fentanyl lozenges, 
bupenorphine sublingual tablets)1 
should be considered.
Alternative routes may also be 
investigated. Bupenorphine and 
fentanyl are available as transdermal 
preparations,1 and paracetamol, 
oxycodone, diclofenac, ketoprofen 
and indomethacin are available as 
suppositories1 (although some are 
low-dose formulations only suitable 
for children). Many drugs are available 
parenterally, however this requires 
specialist administration, is expensive, 
not always suitable for use at home, 
and in some patients there may be 
a lack of venous access or cachexia 
(i.e. there is little subcutaneous fat for 
hypodermoclysis). 
Why suppositories?
Suppositories have been used for 
centuries, dating back to Hippocrates, 
and have been administered by the 
rectal, vaginal and urethral routes. This 
article focuses on suppositories as an 
alternative:
to the oral route in patients with a) 
nausea and vomiting, dysphagia, 
delirium, or gastrointestinal 
absorptive impairment or 
obstruction 
to repeated parenteral injections b) 
in patients with limited venous 
access, immunological deficiencies 
and bleeding disorders, or 
when infusion pumps may c) 
not be available.2–5 Further, 
parenteral administration may 
not be feasible at home owing to 
caregiver limitations, availability of 
technological support and cost.2
From a compounding point of view, 
suppositories are easily prepared and, 
together with appropriate patient and 
carer counselling, may provide an 
effective pain management alternative 
for those patient who have limited 
options. Further, compounding 
suppositories may also allow multiple 
drugs to be delivered in a single 
suppository thereby limiting the 
number of daily insertions.2
Oral solid dosage form
Commercially available oral liquid, 
lozenge or sublingual preparation
Alternative route of administration 
(parenteral, transdermal, rectal)
Figure 1. Management of 
analgesia in practice
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Patient acceptance and 
contraindications
Caregiver willingness and patient 
compliance are limiting factors to 
the use of suppositories. Patient-
related barriers include physical 
disabilities such as arthritis, 
which limits manual dexterity 
and suppository insertion. There 
may also be cultural and ethnic 
differences in acceptance of this 
dosage form. A lack of education 
regarding administration may limit 
dosing. This does however provide 
an opportunity for the pharmacist 
to become involved in counselling 
patients and caregivers on the use 
of suppositories.
Contraindications to the use of 
rectal medicines are relative 
rather than absolute. Medical 
contraindications include neuropathy 
(<500 neutrophils per microlitre), 
thrombocytopenia (<20,000 
platelets per microlitre), diarrhoea, 
anorectal disease such as perianal 
abscess and fistulas, and prior 
abdominoperineal resection.2
New developments
Davis, et al.2 have reviewed 
medicines administered rectally 
in cancer patients, including the 
suppository bases used and 
bioavailability for each active 
ingredient. In recent years, 
there have been many unique 
suppositories investigated including 
hollow-type suppositories, hydrogel 
suppositories, layered-double or 
triple suppositories, reversed-
micellar-solution suppositories, 
sustained release suppositories 
(cellulose derivatives, carboxyvinyl 
polymers, or alginic acid), thermo-
reversible-liquid suppositories 
and effervescent suppositories.6 
A study by Moolenaar, et al.7 
reported the clinical efficacy, 
safety and pharmacokinetics of 
a controlled release morphine 
sulphate suppository. The sustained-
release suppository can be used 
to avoid the four-hourly rectal 
dosing schedule, usually required 
due to the fast rectal absorption 
and elimination of morphine. Each 
suppository contained 30.0 mg 
morphine sulphate, 108 mg aerosil 
R972, 300 mg hydroxypropyl 
methylcellulose (HPMC) 4,000 and 
2,390 mg Witepsol W25.
Compounding suppositories
Active ingredient
Options available include sourcing 
the active ingredient as a pure drug 
powder or alternatively tablet or 
capsule contents can be used. The use 
of capsules is preferred over tablets 
due to the ease of use and that they 
generally contain fewer excipients 
(this can be evaluated by comparing 
the CMIs of the solid oral dosage 
forms available). 
Excipients/suppository bases
Suppository bases
Four classifications of suppository 
bases are usually described. The 
most common are (i) the fatty 
or oleaginous (oil type) bases 
which melt at body temperature 
to release the medication, and (ii) 
the water-soluble or water-miscible 
polymer bases where the drug is 
released as a consequence of the 
progressive dissolution of the base 
into the intrarectal aqueous phase. 
Glycerin-gelatin bases (iii) are seldom 
used except as laxatives. The fourth 
group of bases (iv) contain various 
ingredients including disintegrating 
agents, natural gums, effervescent 
agents, collagen, and fibrin.6
Fatty or oleaginous bases: the most 
frequently employed suppository 
bases, principally because cocoa 
butter (theobroma oil) is a fatty 
base. Ingredients used in these 
bases include hydrogenated fatty 
acids of vegetable oils such as 
palm kernel oil and cottonseed oil, 
glyceryl monostearate, and glyceryl 
monopalmitate. Commercially 
available fatty bases are often 
prepared with the fatty materials 
emulsified or with an emulsifying 
agent, which emulsifies when the 
suppository makes contact with the 
aqueous body fluids.6
Water-soluble and water-miscible 
polymer bases: consist mainly of 
polyethylene glycols (PEGs) and 
poloxomers. PEGs are polymers of 
ethylene oxide and water, prepared 
to various chain lengths, molecular 
weights and physical states. The 
numerical designations of PEGs refer 
to the average molecular weights 
of each of the polymers, with the 
hardness increasing with an increase 
in the molecular weight, e.g. 300, 400 
and 600 are clear, colourless liquids, 
and 1,000 and above are wax-like, 
white solids. Various combinations 
of PEGs may be combined by fusion 
to achieve a base of the desired 
consistency and characteristics. 
Commercially available bases contain 
combinations of the various PEGs in 
appropriate proportions.6
How to choose a suppository base
The lipid-water partition coefficient of 
a drug is an important consideration 
in the selection of the base and 
in anticipating drug release from 
that base. A lipophilic drug that is 
distributed in a fatty base in low 
concentration has less of a tendency 
to escape to the surrounding aqueous 
rectal fluids than a hydrophilic drug. 
However, water soluble bases which 
dissolve in the anorectal fluids will 
release both water-soluble and 
oil-soluble drugs for absorption. 
Excipients
Suppositories may include suspending 
agents (e.g. micronised silica gel) to 
suspend the active ingredient, ensure 
content uniformity of the final product 
and thus accurate dosing.
Method
In the absence of compendial 1. 
or other formulae, calculate the 
required quantity of each ingredient 
for the total amount required 
and determine the appropriate 
suppository base to be used 
(see Figure 3).
The active ingredient should be 2. 
ground into a fine powder in a 
mortar and pestle. A small particle 
size is desirable for drugs present 
Figure 2. How to choose a suppository base
Lipophilic drug or drug in  
unionised (non-salt) form
Water-soluble base
Hydrophilic drug or drug  
in ionised (salt) form
Fatty base
Water-soluble 
base
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in the undissolved state, since this 
will facilitate dissolution, absorption 
and result in good bioavailability. 
This is of particular importance 
for those drugs with limited water 
solubility.
Excipients such as suspending 3. 
agents should be incorporated using 
the principal of geometric dilution.
The suppository base should be 4. 
melted using low heat, since 
many bases are sensitive to high 
temperatures.
The powdered ingredients should 5. 
then be incorporated by slow 
sprinkling on the surface of the 
melt, with constant stirring.
The base should be allowed to 6. 
cool slightly before pouring into a 
suitable mould. To ensure content 
uniformity of each suppository, the 
base should be poured immediately 
after stirring.
The suppositories should be 7. 
appropriately labelled and packaged. 
Calibration of suppository moulds 
and displacement values
When an amount as a dose (as distinct 
from a percentage) of medicament is 
prescribed, it is necessary to make an 
allowance for the volume occupied by 
the medicament in each suppository 
(i.e. displacement value). APF218 
provides displacement values for a 
limited number of drugs. It is also 
important to calibrate the suppository 
mould with the suppository base to be 
used. Suppliers of suppository moulds 
will usually provide this information 
with their equipment.
Packaging
Suppositories may be individually 
wrapped in foil and placed in a sealed 
container (e.g. 50 g ointment jar), 
or supplied in a disposable mould. 
Contact your local supplier for 
equipment and packaging options.
Labelling
Compounded products are to be 
labelled according to regulatory 
requirements9 and should include 
the approved pharmacopoeial name 
(where applicable) and the name and 
strength of any preservatives used. The 
label must also be in accordance with 
the relevant state law.8 A complete 
list of ingredients and their amounts/
Step 1: Is the drug in a salt form? How many waters are 
attached or is it anhydrous? 
Morphine (Mw 285.3): C•	 17H19NO3 
Morphine sulphate (Mw 758.8): (C•	 17H19NO3)2,H2SO4,5H2O  
Note: there are 2 morphine molecules and 5 waters in this salt.
Morphine HCl (Mw 375.8): C•	 17H19NO3,HCl,3H2O
Note: there is 1 morphine molecule and 3 waters in this salt.
Conversion calculations:
How much morphine is in 25 mg of morphine sulphate?•	
Answer: 285.3 x 2/758.8 x 25 = 18.79 mg of morphine.
Tip: To determine how much morphine is in morphine sulphate multiply the 
sulphate by 0.75.
How do I convert an amount of morphine sulphate to morphine •	
hydrochloride (HCl)?
Answer: 285.3/375.8 x 25 = 18.98 mg of morphine in morphine HCl
Tip: To determine how much morphine HCl is equivalent to the sulphate 
multiply the amount of morphine sulphate by 0.99 (i.e. 24.75 mg of the 
HCl ~ 25 mg of the sulphate).
Step 2: Choose a suitable suppository base.
Morphine – unionised (non-salt), therefore use a water-soluble base.•	
Morphine sulphate or HCl – water-soluble (ionised salt), therefore either base.•	
proportions should be included when 
non-pharmacopoeial products are 
prepared. Ancillary labels should be 
used to indicate specific storage 
conditions, provide an expiry date and 
indicate specific usage conditions. 
Suitable labels to indicate internal or 
external use, such as Label L CAUTION 
NOT TO BE TAKEN should be included.
Storage
In the absence of any published 
stability data, the APF recommends 
an expiry date 28 days from that of 
manufacture.8 Suppositories should 
be stored in a cool (<25ºC), dry 
place, protected from light. Ideally, 
polyethylene glycol and Witepsol 
bases should not be stored in the 
refrigerator due to problems with 
cracking, however in certain regions of 
Australia, where there are extremes of 
temperature and humidity; refrigeration 
(2–8ºC) may be the only option. 
Quality control and  
self-inspection
The pharmacist is responsible 
for ensuring the quality of 
extemporaneously prepared products 
and should verify that products are 
prepared according to documented 
procedures and meet product 
specifications before releasing them 
for dispensing.8 Self-inspections 
should also be conducted at regular 
intervals to identify areas for 
improvement and the resulting actions 
should be documented.8
Counselling/instructions 
for patients
Important counselling information 
would include the usefulness of 
suppositories as a dosage form and 
also establishing whether there are 
any patient or carer barriers to the use 
of this dosage form. Directions for use 
should include the following (adapted 
from Proladone (oxycodone pectinate) 
CMI10):
If possible, go to the toilet and •	
empty your bowels before using 
your suppository. 
Wash your hands thoroughly with •	
soap and water.
If the suppository is too soft to use, •	
put it in the refrigerator for about 
15 minutes. (The instruction to 
chill by holding it under cold water 
for a few minutes should only be 
Figure 3. Calculation of the amount of active ingredient and 
choice of base – an example
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used if the packaging protects the 
suppository from water.)
Put on a disposable glove, •	
if desired. (These may be supplied 
with the suppositories.)
Remove the suppository from the •	
packaging. (If suppositories are 
supplied in a disposable mould, 
detailed instructions should be 
given on how to remove it.)
Moisten the suppository by dipping •	
it briefly in cool water. (This will 
provide lubrication and is especially 
important for water soluble bases 
that can cause pain due to their 
hygroscopic nature.) 
Lie on your side and raise your knee •	
to your chest. Push the suppository 
gently, pointed end first, into your 
rectum (back passage). (Some may 
argue that retention is superior 
when the base rather than the apex 
is delivered first, since the lower 
edge of the external sphincter 
contracts along the edge of the apex 
forcing the suppository upwards, 
which facilitates retention.)2
Remain lying down for a few •	
minutes, to allow the suppository to 
melt/dissolve.
Throw away used materials and •	
wash your hands thoroughly.
Try not to go to the toilet for at least •	
an hour after using the suppository. 
If you are not sure how to use a •	
suppository, ask your pharmacist.
Pharmacist role
Suppositories provide a practical 
example for pharmacists across 
all areas of practice in community, 
hospital and aged care of how 
compounding can be used to 
enhance the safe and effective 
use of medicines to meet patients’ 
specific needs. Pharmacists have an 
important role to play in educating 
patients and carers of the usefulness 
of this dosage form and overcoming 
psychological barriers to their use.
Key learning points
Patients’ unique needs for •	
pain medication may be met 
by pharmacists compounding 
suppositories, where other routes of 
administration are not available.
It is important to determine the •	
amount of active ingredient for the 
suppository taking into account the 
type of salt (e.g. sulphate/HCl) and 
whether it is anhydrous or not.
Choice of a suitable base is the next •	
step in the process of compounding 
suppositories. For drugs which are in 
their ionised (salt) form (e.g. sulphate/
HCl/sodium), both water-soluble and 
fatty bases can be used, although 
fatty bases are often preferred, 
because the water-soluble bases may 
cause evacuation in some patients. 
However, fatty bases are not suitable 
for the non-salt form of the drug. 
Labelling and packaging the •	
suppositories appropriately is then 
undertaken with consideration given 
as to how they will be stored.
Counselling of the patient on storage •	
(<25ºC), expiry (28 days) and use 
is the final responsibility of the 
pharmacist in this process. 
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1. There are several reasons 
why a patient may require 
administration of their oral 
opioids via the rectal route. 
Which ONE of the following 
reasons is INCORRECT?
a) Patients are unable or unwilling to 
swallow.
b) Patients are suffering from severe 
nausea and vomiting.
c) Patients require their medication to 
be delivered at home.
d) Patients have access to infusion 
pumps.
e) Patients with immunological 
deficiencies and bleeding disorders 
are unable to have repeated 
parenteral injections.
2. Which of the following drugs 
used in pain management is not 
suitable for compounding in a 
fatty suppository base?
a) Morphine sulphate.
b) Oxycodone HCl.
c) Indomethacin sodium.
d) Methadone HCl.
e) Hydromorphone.
3. Given the following formula (per 
suppository):
Morphine sulphate  30 mg
Aerosil R972  108 mg
HPMC 4000  300 mg
Witepsol W 25 2,390 mg
You have been supplied with 
morphine HCl. How much 
morphine HCl do you need 
per suppository to deliver the 
required dose of morphine?
a) 29.7 mg.
b) 30 mg.
c) 22.5 mg.
d) 33 mg.
e) 15 mg.
Questions  A score of 3 out of 4 attracts three quarters of a credit point.
4. Packaging, labelling and storage 
of compounded suppositories 
are the responsibility of 
the pharmacist. Which of 
the following statements is 
CORRECT?
a) Suppositories should be 
individually wrapped in foil, but do 
not need to be placed in sealed 
container.
b) Labelling requires the inclusion of 
the pharmacological name of the 
drug ONLY.
c) “CAUTION NOT TO BE TAKEN” 
need not be included on the label.
d) An expiry date of 3 months 
from the date of manufacture is 
acceptable.
e) Although storage below 25ºC is 
recommended, refrigeration may 
be required in certain climatic 
regions of Australia.
